Q93. Match the chemicals listed in Column I with the developmental physiological defects listed in Column II
| Column I | Column II |
|---|---|
| P. Veratrum alkaloids | (i) Cyclopia syndrome |
| Q. Thalidomide | (ii) Phocomelia |
| R. Diethylstilbestrol | (iii) Minamata syndrome |
| S. Methylmercury | (iv) Obesity syndrome |
| (A) P-(iii), Q-(iv), R-(ii), S-(i) | |
| (B) P-(i), Q-(iv), R-(iii), S-(ii) | |
| (C) P-(ii), Q-(iv), R-(iii), S-(i) | |
| (D) P-(ii), Q-(iii), R-(iv), S-(i) |
Teratogens and Developmental Defects: Matching Chemicals to Birth Anomalies
Veratrum alkaloids, thalidomide, and diethylstilbestrol each link to specific developmental defects through teratogenic mechanisms studied in embryology. This matching question tests knowledge of their precise effects on fetal development. The correct pairing is option (A): P-(iii), Q-(iv), R-(i).
Question Breakdown
Column I lists teratogenic chemicals: P. Veratrum alkaloids, Q. Thalidomide, R. Diethylstilbestrol. Column II lists defects: (i) Obesity syndrome, (ii) Minamata syndrome, (iii) Cyclopia, (iv) Phocomelia.
Option Analysis
Option (A): P-(iii) Q-(iv) R-(i)
Veratrum alkaloids (cyclopamine) cause cyclopia by inhibiting Sonic hedgehog signaling, leading to holoprosencephaly and fused eyes. Thalidomide triggers phocomelia via anti-angiogenic effects, halting limb bud vessel growth and causing proximal limb absence. Diethylstilbestrol (DES) associates with obesity syndrome through prenatal exposure disrupting metabolic programming and adiposity. This matches perfectly.
Option (B): P-(i) Q-(iv) R-(ii)
Pairs Veratrum with obesity (incorrect; links to cyclopia), thalidomide with phocomelia (correct), DES with Minamata (wrong; Minamata ties to methylmercury, not DES).
Option (C): P-(ii) Q-(iv) R-(iii)
Assigns Veratrum to Minamata (false), thalidomide to phocomelia (correct), DES to cyclopia (no evidence).
Option (D): P-(ii) Q-(iii) R-(iv)
Links Veratrum to Minamata (incorrect), thalidomide to cyclopia (wrong), DES to phocomelia (unrelated).
Veratrum alkaloids, thalidomide, and diethylstilbestrol represent key teratogens causing specific developmental defects, vital for CSIR NET life sciences preparation. These agents disrupt embryogenesis at critical windows, leading to anomalies like cyclopia, phocomelia, and obesity syndrome. Understanding their matching enhances mastery of teratology.
Key Teratogen-Defect Pairings
-
Veratrum alkaloids → Cyclopia: Steroidal alkaloids like cyclopamine from Veratrum californicum block Shh signaling during gastrulation, fusing forebrain and eyes in lambs and models.
-
Thalidomide → Phocomelia: This sedative inhibits angiogenesis in limb buds (days 20-36 gestation), causing flipper-like limbs via vessel loss and cell death.
-
Diethylstilbestrol (DES) → Obesity syndrome: Prenatal exposure reprograms metabolism, raising adult obesity risk through endocrine disruption and adipocyte changes.
-
Thalidomide ≠ Minamata syndrome: Minamata involves methylmercury neurotoxicity, not thalidomide.
Mechanisms in Detail
Teratogens act via distinct pathways: Veratrum disrupts Hedgehog for midline defects; thalidomide targets vessels for limb truncations; DES alters epigenetics for later obesity. Timing matters—e.g., Veratrum on gestation day 14 induces cyclopia in sheep.
| Teratogen | Primary Defect | Mechanism | Exposure Window |
|---|---|---|---|
| Veratrum alkaloids | Cyclopia | Shh inhibition | Gastrulation |
| Thalidomide | Phocomelia | Anti-angiogenesis | Limb bud (20-36 days) |
| Diethylstilbestrol | Obesity syndrome | Metabolic programming | Prenatal |
| Methylmercury | Minamata syndrome | Neurotoxicity | Fetal |
